Today's Information

Provided by: TaiMed Biologics Inc.
SEQ_NO 6 Date of announcement 2022/05/30 Time of announcement 15:50:10
Subject 
 2022 general shareholders' meeting approved the
lifting of non-competition restrictions for directors
Date of events 2022/05/30 To which item it meets paragraph 21
Statement 
1.Date of the shareholders' meeting resolution:2022/05/30
2.Name and title of the managerial officer with permission
 to engage in competitive conduct:
 (1) Director: Frank Chen(Representative of Chang Chun Investment)
 (2) Director: Tien-Chieh, Lee(Representative of Huei Hong Investment)
 (3) Director: Tamon Tseng(Representative of Yi Tai Investment)
 (4) Director: Shih Chia Lin(Representative of National Development Fund)
 (5) Independent director：Howard S. Lee
 (6) Institutional director：National Development Fund
3.Items of competitive conduct in which the officer is
permitted to engage:
 Investing in or managing a third party operating in a scope of business
 similar to that of the Company
4.Period of permission to engage in the competitive conduct:
 For the duration of serving as a director of the Company
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
 The proposal has been passed as is by a two thirds vote of the
 shareholders present in a meeting attended by shareholders representing
 a majority or more of the shares outstanding.
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter "N/A" below):N/A
7.Company name of the mainland China enterprise and the
officer's position in the enterprise:N/A
8.Address of the mainland China enterprise:N/A
9.Operations of the mainland China enterprise:N/A
10.Impact on the company's finance and business:None
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:N/A
12.Any other matters that need to be specified:None

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

TaiMed Biologics Inc. published this content on 30 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 May 2022 14:38:07 UTC.